News & Updates

Show Multimedia Only
Empagliflozin lowers mortality, cardiorenal events even in COPD presence Empagliflozin lowers mortality, cardiorenal events even in COPD presence

Empagliflozin lowers mortality, cardiorenal events even in COPD presence

28 Mar 2022 byJairia Dela Cruz

Among patients with type 2 diabetes mellitus and cardiovascular disease, those with concomitant chronic obstructive pulmonary disease (COPD) are at higher risk of mortality and adverse cardiorenal outcomes, including heart failure, according to post hoc analyses of the EMPA-REG OUTCOME trial. However, these outcomes can be prevented with empagliflozin treatment, regardless of the presence of COPD.

28 Mar 2022
Omicron more stable than ancestral strain on surfaces, resistant to neutralizing mAbs

Omicron more stable than ancestral strain on surfaces, resistant to neutralizing mAbs

21 Mar 2022 byChristina Lau

The Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is more stable than the ancestral strain on various smooth and porous surfaces and demonstrates marked resistance to neutralizing monoclonal antibodies (mAbs), researchers from the University of Hong Kong (HKU) have reported.

21 Mar 2022
Asthma, COPD up chronic otitis media risk

Asthma, COPD up chronic otitis media risk

19 Mar 2022

Patients with asthma or chronic obstructive pulmonary disease (COPD) may be at a higher risk of chronic otitis media, reports a recent study.

19 Mar 2022